“The existing problem has uncovered some structural weaknesses within the EU’s medicines source chain in addition to a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides mentioned. She proposed that offer chain challenges be dealt with in an EU pharmaceutical tactic expected to get introdu